Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd.

Shoba Amarnath, PhD, Carliann M Costanzo, Jason Foley, MS, MBA, Jacopo Mariotti, Daniel M Konecki, ANu Gangopadhyay, Michael Eckhaus, Susan Wong, Bruce Levine, PhD, Carl H. June, MD, Daniel H. Fowler

Blood (2009) 114 (22): 2456.

https://doi.org/10.1182/blood.V114.22.2456.2456

Published: 2009

Journal Articles

Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival.

Blood (2009) 114 (22): 784.

https://doi.org/10.1182/blood.V114.22.784.784

Published: 2009

Journal Articles

Influenza (flu) Vaccine Administration to Patients with Multiple Myeloma (MM) Prior to Autologous T-Cell Harvest Leads to Better Reconstitution of Flu Immunity After High Dose Melphalan and Autologous Stem Cell Transplant (ASCT) and Reinfusion of Primed Ex-Vivo Co-Stimulated Autologous T-Cells and Post-ASCT Second Flu Vaccination Than Post-ASCT Flu Vaccination Alone.

Edward A. Stadtmauer, MD, Dan T. Vogl, MD, Nicole A. Aqui, MD, Aaron P. Rapoport, MD, Kenyetta Macdonald, Heather Murphy, Rita Bhagat, RN, Patricia A. Mangan, APRN, BC, Anne Chew, PhD, Elizabeth Veloso, RN, JD, Bruce Levine, PhD, Robert H. Vonderheide, MD, DPhil, Carl H. June, MD, Kathleen Sullivan, MD

Blood (2009) 114 (22): 797.

https://doi.org/10.1182/blood.V114.22.797.797

Published: 2009

Journal Articles

Artificial Antigen Presenting Cells (aAPC) Expanded NK-Mediated Enhanced Lysis of Allogeneic Tumor Cells Regardless of HLA Class I/KIR Mismatch and Its Implication of Use in Eradicating Acute Lymphoblastic Leukemia (ALL).

Hua Zhang, Bruce Levine, PhD, Nga Voong, Alan S. Wayne, MD, Carl H. June, MD, Crystal L. Mackall, M.D.

Blood (2009) 114 (22): 3023.

https://doi.org/10.1182/blood.V114.22.3023.3023

Published: 2009

Journal Articles

PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression.

Shoba Amarnath, PhD, James CM Wang, Paul R. Massey, James L. Riley, Bruce Levine, PhD, Carl H. June, MD, Jeffrey A. Medin, PhD, Daniel Fowler, MD

Blood (2009) 114 (22): 3580.

https://doi.org/10.1182/blood.V114.22.3580.3580

Published: 2009

Journal Articles

Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells.

Emily Bunce, Justin Taylor, Jason Foley, MS, MBA, Bruce Levine, PhD, Carl H. June, MD, Marianna Sabatino, Vicki Fellowes, David Stroncek, Daniel H Fowler, MD, Shoba Amarnath, PhD

Blood (2009) 114 (22): 501.

https://doi.org/10.1182/blood.V114.22.501.501

Published: 2009

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

Journal Articles

Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans.

Boro Dropulic, PhD, Laurent Humeau, PhD, Vladimir Slepushkin, MD, PhD, Xiaobin Lu, PhD, Peter Manilla, MA, Tessio Rebello, PhD, Cathleen Afable, MA, CQA, Kim Lacy, RN, Cathy Ybarra, BSN, RN, Bruce Levine, PhD, Carl June, MD, Rob Roy MacGregor, MD

Blood (2004) 104 (11): 411.

https://doi.org/10.1182/blood.V104.11.411.411

Published: 2004

Journal Articles

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

David Porter, MD, Bruce Levine, PhD, Nancy Bunin, MD, Edward Stadtmauer, MD, Selina Luger, MD, Steven Goldstein, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Julie Oliver, CRNP, Ambika Sohal, Liz Veloso, RN, Stephen Emerson, MD, PhD, Carl June, MD

Blood (2004) 104 (11): 1640.

https://doi.org/10.1182/blood.V104.11.1640.1640

Published: 2004

NARROW

Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd.

Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival.

Artificial Antigen Presenting Cells (aAPC) Expanded NK-Mediated Enhanced Lysis of Allogeneic Tumor Cells Regardless of HLA Class I/KIR Mismatch and Its Implication of Use in Eradicating Acute Lymphoblastic Leukemia (ALL).

PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression.

Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells.

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans.

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only